Obtenga las últimas noticias sobre las acciones de HCW Biologics con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de HCWB

Últimas noticias sobre

HCW Biologics

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

HCW Biologics Inc

Earnings

Press Releases

HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

News

General

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

Health Care

HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

Opinion

Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics

Financing

HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor "What This Means" Segment About its Proprietary T-Cell Engager Program

HCW Biologics' Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer

HCW Biologics to Participate in the 2025 Maxim Growth Summit

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor "What This Means" Segment

AVAI

HCWB

QURE

SLDB

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Alzamend Neuro

Aprea Therapeutics

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Ensysce Biosciences

Entero Therapeutics

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals

Galecto

GT Biopharma

IN8bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Mainz Biomed

Neuphoria Therapeutics Inc. - Common Stock

Neuphoria Therapeutics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sunshine Biopharma

SILO Pharma

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Theriva Biologics

VivoSim Labs

Xenetic Biosciences

XTL Biopharmaceuticals Ltd. - American Depositary Shares

Comments

HCW Biologics Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL